

DAFTAR PUSTAKA

- Alsaad, S., Addweesh, A., Beyari, M., Alkhateb, M., Alswat, A., Alshabnan, A., Alsaad, A., & Alsaif, H. (2022). Comorbidities associated with risk of ICU admission in elderly patients with COVID-19: Data from academic hospital in Saudi Arabia. *Medicine (United States)*, 101(39), E30799. <https://doi.org/10.1097/MD.00000000000030799>
- American Lung Association. (2015). Trends in Pneumonia and Influenza Morbidity and Mortality. *American Lung Association Epidemiology and Statistics Unit Research and Health Education Division*, November, 6. <http://www.lung.org/assets/documents/research/pi-trend-report.pdf>
- Anggraini, W. (2021). Evaluasi Kualitatif Penggunaan Antibiotik Pada Pasien Pneumonia Rs “X” Di Malang. *KELUWIH: Jurnal Kesehatan Dan Kedokteran*, 3(1), 9–21. <https://doi.org/10.24123/kesdok.v3i1.2887>
- Apriliany, F. (2022). *RASIONALITAS ANTIBIOTIK EMPIRIS PADA PASIEN HOSPITAL ACQUIRED PNEUMONIA (HAP) DI RSUD PROVINSI NTB*.
- Arayasukawat, P., So-ngern, A., Reechaipichitkul, W., Chumpangern, W., Arunsurat, I., Ratanawatkul, P., & Chuennok, W. (2021). Microorganisms and clinical outcomes of early- and late-onset ventilator-associated pneumonia at Srinagarind Hospital, a tertiary center in Northeastern Thailand. *BMC Pulmonary Medicine*, 21(1), 1–8. <https://doi.org/10.1186/s12890-021-01415-ATS>
- ATS. (2005). Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *American Journal of Respiratory and Critical Care Medicine*, 171(4), 388–416. <https://doi.org/10.1164/rccm.200405-644ST>
- Cao, G., Zhu, Y., Xie, X., Chen, Y., Yu, J., Zhang, J., Chen, Z., Pang, L., Zhang, Y., & Shi, Y. (2020). Pharmacokinetics and pharmacodynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation. *Experimental and Therapeutic Medicine*, 20(1), 607–616. <https://doi.org/10.3892/etm.2020.8715>
- Chao, C. M., Lai, C. C., Lee, C. H., & Tang, H. J. (2022). Optimal Dose of Cefoperazone-Sulbactam for Acute Bacterial Infection in Patients with Chronic Kidney Disease. *Antibiotics*, 11(5), 2–9. <https://doi.org/10.3390/antibiotics11050610>
- Chen, C.-H., Tu, C.-Y., Chen, W.-C., Kuo, L.-K., Wang, Y.-T., Fu, P.-K., Ku, S.-C., Fang, W.-F., Chen, C.-M., & Lai, C.-C. (2021). Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia. *Infection and Drug Resistance*, 14, 2251–2258. <https://doi.org/10.2147/IDR.S313828>
- Chou, C. C., Shen, C. F., Chen, S. J., Chen, H. M., Wang, Y. C., Chang, W. S., Chang, Y. T., Chen, W. Y., Huang, C. Y., Kuo, C. C., Li, M. C., Lin, J. F., Lin, S. P., Ting, S. W., Weng, T. C., Wu, P. S., Wu, U. I., Lin, P. C., Lee, S. S. J., ... Lin, M. C. (2019). Recommendations and guidelines for the treatment of pneumonia in Taiwan. *Journal of Microbiology, Immunology and Infection*, 52(1), 172–199. <https://doi.org/10.1016/j.jmii.2018.11.004>

- Chou, C. Y., Wang, S. M., Liang, C. C., Chang, C. T., Liu, J. H., Wang, I. K., Hsiao, L. C., Muo, C. H., Huang, C. C., & Wang, R. Y. (2014). Risk of pneumonia among patients with chronic kidney disease in outpatient and inpatient settings. *Medicine (United States)*, 93(27), 1–4. <https://doi.org/10.1097/MD.0000000000000174>
- Cillóniz, C., Domínguez, C., & Torres, A. (2019). An overview of guidelines for the management of hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria. *Current Opinion in Infectious Diseases*, 32(6), 656–662. <https://doi.org/10.1097/QCO.0000000000000596>
- Davies, N. M., Holmes, M. V., & Davey Smith, G. (2018). Reading Mendelian randomisation studies: A guide, glossary, and checklist for clinicians. *BMJ (Online)*, 362. <https://doi.org/10.1136/bmj.k601>
- De-Miguel-diez, J., Jimenez-Garcia, R., Hernandez-Barrera, V., De-Miguel-yanes, J. M., Carabantes-Alarcon, D., & Lopez-De-andres, A. (2021). Assessing the impact of gender and copd on the incidence and mortality of hospital-acquired pneumonia. A retrospective cohort study using the spanish national discharge database (2016–2019). *Journal of Clinical Medicine*, 10(22), 1–14. <https://doi.org/10.3390/jcm10225453>
- Dezube, R. (2023). *Effect of aging in respiratory System*.
- DINKES. (2021). Kota Yogyakarta. *Jurnal Kajian Ilmu Administrasi Negara*, 107(38), 107–126. <https://journal.uny.ac.id/index.php/natapraja/article/view/12619>
- Enne, V. I., Personne, Y., Grgic, L., Gant, V., & Zumla, A. (2014). Aetiology of hospital-acquired pneumonia and trends in antimicrobial resistance. *Current Opinion in Pulmonary Medicine*, 20(3), 252–258. <https://doi.org/10.1097/MCP.0000000000000042>
- Gijssen, M., Dreesen, E., Van Daele, R., Annaert, P., Debaveye, Y., Wauters, J., & Spriet, I. (2021). Pharmacokinetic/pharmacodynamic target attainment based on measured versus predicted unbound ceftriaxone concentrations in critically ill patients with pneumonia: An observational cohort study. *Antibiotics*, 10(5). <https://doi.org/10.3390/antibiotics10050557>
- Gonçalves-Pereira, J., Mergulhão, P., Nunes, B., & Froes, F. (2021). Incidence and impact of hospital-acquired pneumonia: a Portuguese nationwide four-year study. *Journal of Hospital Infection*, 112, 1–5. <https://doi.org/10.1016/j.jhin.2021.03.012>
- Guo, S., Du, W., Chen, S., Guo, X., & Ju, X. (2019). Exploring the impact of the rational antibiotic use system on hospital performance: the direct effect and the spillover effect. *International Journal of Environmental Research and Public Health*, 16(18). <https://doi.org/10.3390/ijerph16183463>
- Gyssens, I. C. (2005). *Chapter 12 Audits for Monitoring the Quality of Antimicrobial Prescriptions. Table 1*, 197–198.
- Han, Y., Zhang, J., Zhang, H. Z., Zhang, X. Y., & Wang, Y. M. (2022). Multidrug-resistant organisms in intensive care units and logistic analysis of risk factors. *World Journal of Clinical Cases*, 10(6), 1795–1805. <https://doi.org/10.12998/wjcc.v10.i6.1795>

- Imran, M., Amjad, A., & Haidri, F. R. (2016). Frequency of hospital acquired pneumonia and its microbiological etiology in medical intensive care unit. *Pakistan Journal of Medical Sciences*, 32(4), 823–826. <https://doi.org/10.12669/pjms.324.8942>
- Jiao, J., Li, Z., Wu, X., Cao, J., Liu, G., Liu, Y., Li, F., Zhu, C., Song, B., Jin, J., Liu, Y., Wen, X., Cheng, S., & Wan, X. (2021). Risk factors for 3-month mortality in bedridden patients with hospital-acquired pneumonia: A multicentre prospective study. *PLoS ONE*, 16(3 March 2021), 1–10. <https://doi.org/10.1371/journal.pone.0249198>
- Jones, B. E., Sarvet, A. L., Ying, J., Jin, R., Nevers, M. R., Stern, S. E., Ocho, A., McKenna, C., McLean, L. E., Christensen, M. A., Poland, R. E., Guy, J. S., Sands, K. E., Rhee, C., Young, J. G., & Klompas, M. (2023). Incidence and Outcomes of Non-Ventilator-Associated Hospital-Acquired Pneumonia in 284 US Hospitals Using Electronic Surveillance Criteria. *JAMA Network Open*, 6(5), E2314185. <https://doi.org/10.1001/jamanetworkopen.2023.14185>
- Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O’Grady, N. P., Bartlett, J. G., Carratalà, J., El Solh, A. A., Ewig, S., Fey, P. D., File, T. M., Restrepo, M. I., Roberts, J. A., Waterer, G. W., Cruse, P., Knight, S. L., & Brozek, J. L. (2016). Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clinical Infectious Diseases*, 63(5), e61–e111. <https://doi.org/10.1093/cid/ciw353>
- Kato, H., Hagihara, M., Morikawa, Y., Asai, N., Mikamo, H., & Iwamoto, T. (2022). *Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia*. 1–10.
- Kemkes RI. (2018). Hasil Riset Kesehatan Dasar Tahun 2018. *Kementrian Kesehatan RI*, 53(9), 1689–1699.
- Khadijah, S., Handayani, I., & Sennang, N. (2019). PREVALENCE AND CHARACTERISTIC MULTIDRUG RESISTANT ORGANISMS IN INTENSIVE CARE UNIT OF Dr. WAHIDIN SUDIROHUSODO HOSPITAL MAKASSAR. *Indonesian Journal of Clinical Pathology and Medical Laboratory*, 25(3), 323–327. <https://doi.org/10.24293/ijcpml.v25i3.1453>
- Kim, B. G., Kang, M., Lim, J., Lee, J., Kang, D., Kim, M., Kim, J., Park, H., Min, K. H., Cho, J., & Jeon, K. (2022). Comprehensive risk assessment for hospital-acquired pneumonia: sociodemographic, clinical, and hospital environmental factors associated with the incidence of hospital-acquired pneumonia. *BMC Pulmonary Medicine*, 22(1), 1–11. <https://doi.org/10.1186/s12890-021-01816-9>

- Liu, J. W., Chen, Y. H., Lee, W. Sen, Lin, J. C., Huang, C. T., Lin, H. H., Liu, Y. C., Chuang, Y. C., Tang, H. J., Chen, Y. S., Ko, W. C., Lu, M. C., & Wang, F. Der. (2019). Randomized noninferiority trial of cefoperazone-sulbactam versus cefepime in the treatment of hospital-acquired and healthcare-associated pneumonia. *Antimicrobial Agents and Chemotherapy*, 63(8), 1–10. <https://doi.org/10.1128/AAC.00023-19>
- López-de-Andrés, A., Albaladejo-Vicente, R., de Miguel-Diez, J., Hernández-Barrera, V., Ji, Z., Zamorano-León, J. J., Lopez-Herranz, M., Carabantes Alarcon, D., & Jimenez-Garcia, R. (2021). Gender differences in incidence and in-hospital outcomes of community-acquired, ventilator-associated and nonventilator hospital-acquired pneumonia in Spain. *International Journal of Clinical Practice*, 75(3), 0–1. <https://doi.org/10.1111/ijcp.13762>
- Luckraz, H., Manga, N., Senanayake, E. L., Abdelaziz, M., Gopal, S., Charman, S. C., Giri, R., Oppong, R., & Andronis, L. (2018). Cost of treating ventilator-associated pneumonia post cardiac surgery in the National Health Service: Results from a propensity-matched cohort study. *Journal of the Intensive Care Society*, 19(2), 94–100. <https://doi.org/10.1177/1751143717740804>
- Marlot C. Kallen, J. M. P. (2017). A systematic review of quality indicators for appropriate antibiotic use in hospitalized adult patients. *[Infectious Disease Reports]*, 9(11), 12–14, 16, 18. <https://doi.org/10.4081/idr.2017>
- Michael Cotten, C., Taylor, S., Stoll, B., Goldberg, R. N., Hansen, N. I., Sanchez, P. J., Ambalavanan, N., & Benjamin, D. K. (2009). Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. *Pediatrics*, 123(1), 58–66. <https://doi.org/10.1542/peds.2007-3423>
- Minar Paskah Lianti Manik, Rizka Humardewayanti Asdie, & Ika Puspitasari. (2020). Evaluation of empirical antibiotic usage and cost analysis of patients with nosocomial pneumonia in ICU of RSUP Dr. Sardjito, yogyakarta. *Indonesian Journal of Pharmacology and Therapy*, 1(2), 79–88. <https://doi.org/10.22146/ijpther.573>
- Mizgerd, J. P. (2018). Inflammation and Pneumonia: Why Are Some More Susceptible than Others? *Clinics in Chest Medicine*, 39(4), 669–676. <https://doi.org/10.1016/j.ccm.2018.07.002>
- Modi, A. R., & Kovacs, C. S. (2020). Hospital-acquired and ventilator-associated pneumonia: Diagnosis, management, and prevention. *Cleveland Clinic Journal of Medicine*, 87(10), 633–639. <https://doi.org/10.3949/CCJM.87A.19117>
- Morris, A. C. (2018). Management of pneumonia in intensive care. *Journal of Emergency and Critical Care Medicine*, 2(November), 101–101. <https://doi.org/10.21037/jeccm.2018.11.06>
- Nurhayati, D. H., Setyoningrum, R. A., Utariani, A., & Dharmawati, I. (2021). Risk Factors for Mortality in Children with Hospital-Acquired Pneumonia in Dr. Soetomo General Hospital Surabaya. *Jurnal Respirasi*, 7(2), 46. <https://doi.org/10.20473/jr.v7-i.2.2021.46-52>

- Oderda, G. M. (2002). OUTCOMES AND PHARMACOECONOMICS IN PAIN & PALLIATIVE CARE The Importance of Perspective in Pharmacoeconomic Analyses. *Journal of Pain & Palliative Care Pharmacotherapy*, 16(4), 65–69.
- PDPI. (2018). Tatalaksana terapi HAP-VAP PDPI 2018.
- Perhimpunan Dokter Paru Indonesia. (2003). Pneumonia : Pedoman Diagnosis dan Tata Laksana Medis. *Ikatan Dokter Indonesia*, 19, 19–22.
- Perhimpunan Dokter Paru Indonesia. (2021). Panduan Umum Praktik Klinis Penyakit Paru dan Pernapasan. *PDPI*.
- Permenkes RI. (2021). Pedoman Penggunaan Antibiotik. *Permenkes RI*, 1–97.
- Polat, M. (2017). Pneumonia in patients with diabetes mellitus: A single center experience. *Eurasian Journal of Medicine and Oncology*, 1(1), 14–18. <https://doi.org/10.14744/ejmo.2017.30974>
- Ramadhanti, S., Farmasi, F., & Farmasi, P. P. (2018). *Evaluasi kualitatif penggunaan antibiotik pada pasien ventilator associated pneumonia (vap) dengan metode gyssens di ruang icu rs kanker dharmais jakarta*.
- Robert Cronin Yung Peng, Rose Khavari, N. D. (2017). 乳鼠心肌提取 HHS Public Access. *Physiology & Behavior*, 176(3), 139–148. <https://doi.org/10.1159/000444169>.Carotid
- RSAUGM. (2018). *Panduan Penggunaan Antimikroba RS Akademik UGM*.
- Savitri, A. A., Nuryastuti, T., & Puspitasari, I. (2022). Analisis Rasionalitas Penggunaan Antibiotik Empiris Dan Definitif Pada Terapi Pneumonia Dan Profil Antibiogram di Rumah Sakit Akademik Universitas Gadjah Mada. *Majalah Farmaseutik*, 18(2). <https://doi.org/10.22146/farmaseutik.v1i1.60556>
- Shahnaz Desianti Khoiriyah dan Keri Lestari. (2018). REVIEW ARTIKEL: KAJIAN FARMAKOEKONOMI YANG MENDASARI PEMILIHAN PENGOBATAN DI INDONESIA. *Farmaka*, 16(2), 105–112. <https://doi.org/10.24123/mpi.v2i2.1391>
- Thompson, A. M., Thomas, S. E., Schafers, S. J., Hartmann, A. P., Call, W. B., Bushwitz, J., & Deal, E. N. (2015). The role of azithromycin in healthcare-associated pneumonia treatment. *Journal of Clinical Pharmacy and Therapeutics*, 40(5), 517–524. <https://doi.org/10.1111/jcpt.12319>
- Tjandrawinata, R. R. (2016a). Peran Farmaekonomi dalam Penentuan Kebijakan yang Berkaitan dengan Obat-Obatan. *Working Paper of Dexa Medica Group*, 29(26 January 2016), 46–52.
- Tjandrawinata, R. R. (2016b). Peran Farmakoekonomi dalam Penentuan Kebijakan yang Berkaitan dengan Obat-Obatan. *Medicinus*, 29(1), 46–52.
- Warganegara, E. (2017). Pneumonia Nosokomial: Hospital-Acquired, Ventilator-Associated, dan Health Care-Associated. *Jurnal Kedokteran Unila*, 1(3), 612–618. <http://juke.kedokteran.unila.ac.id/index.php/JK/article/view/1729>
- Wells BG, Dipiro JT, Dipiro CV, S. T. (2015). *Pharmacotherapy Handbook* (Vol. 9).
- Yeh, J. J., Lin, C. L., & Kao, C. H. (2019). Relationship between pneumonia and cardiovascular diseases: A retrospective cohort study of the general population. *European Journal of Internal Medicine*, 59(2), 39–45. <https://doi.org/10.1016/j.ejim.2018.08.003>

- Zhao, X., Wu, J. fang, Xiu, Q. yu, Wang, C., Zhang, D. ping, Huang, J. an, Xie, C. mao, Sun, S. hua, Lv, X. ju, Si, B., Xiao, Z. ke, & Zhang, Y. yuan. (2014). A randomized controlled clinical trial of levofloxacin 750 mg versus 500 mg intravenous infusion in the treatment of community-acquired pneumonia. *Diagnostic Microbiology and Infectious Disease*, 80(2), 141–147. <https://doi.org/10.1016/j.diagmicrobio.2013.11.008>
- Zhou, Y., Yu, F., Yu, Y., Zhang, Y., & Jiang, Y. (2021). Clinical significance of MDRO screening and infection risk factor analysis in the ICU. *American Journal of Translational Research*, 13(4), 3717–3723.